David Wurtman

Company: Geneos Therapeutics, Inc.

Job title: Chief Business Officer

Seminars:

ctDNA Analysis Enhances MRI-Based (RECIST) Assessment of Response in Clinical Trial of Second-Line Advanced HCC 12:30 pm

ctDNA highlights molecular responses to resolve lack of clarity from MRI images alone Combining ctDNA with MRI allows for broader, and earlier, detection of response in second-line advanced HCC to enhance clinical trial readout ctDNA-guided monitoring supports ongoing personalized treatment to improve optimize patient outcomes by elucidating potential basis for immune escape and offering design…Read more

day: Conference Day 1